142 related articles for article (PubMed ID: 18698541)
1. Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
Nessler J; Nessler B; Kitliński M; Stepniewski M; Piwowarska W
Cardiol J; 2008; 15(4):329-37. PubMed ID: 18698541
[TBL] [Abstract][Full Text] [Related]
2. Echo-Doppler mitral flow monitoring: an operative tool to evaluate day-to-day tolerance to and effectiveness of beta-adrenergic blocking agent therapy in patients with chronic heart failure.
Capomolla S; Pinna GD; Febo O; Caporotondi A; Guazzotti G; La Rovere MT; Gnemmi M; Mortara A; Maestri R; Cobelli F
J Am Coll Cardiol; 2001 Nov; 38(6):1675-84. PubMed ID: 11704380
[TBL] [Abstract][Full Text] [Related]
3. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Nessler J; Nessler B; Kitliński M; Gackowski A; Piwowarska W; Stepniewski M
Kardiol Pol; 2008 Feb; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
[TBL] [Abstract][Full Text] [Related]
4. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
5. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
Fragasso G; Spoladore R; Maranta F; Corti A; Lattuada G; Colombo B; Locatelli M; Salerno A; Calori G; Briceno L; Alfieri AB; Perseghin G; Margonato A
J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):49-56. PubMed ID: 23018486
[TBL] [Abstract][Full Text] [Related]
6. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
[TBL] [Abstract][Full Text] [Related]
7. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
[TBL] [Abstract][Full Text] [Related]
8. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
[TBL] [Abstract][Full Text] [Related]
9. Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
Kojima M; Sato K; Kimura G; Ueda R; Dohi Y
J Cardiovasc Pharmacol; 2007 Apr; 49(4):191-6. PubMed ID: 17438403
[TBL] [Abstract][Full Text] [Related]
10. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).
Bergström A; Andersson B; Edner M; Nylander E; Persson H; Dahlström U
Eur J Heart Fail; 2004 Jun; 6(4):453-61. PubMed ID: 15182771
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Frantz RP; Olson LJ; Grill D; Moualla SK; Nelson SM; Nobrega TP; Hanna RD; Backes RJ; Mookadam F; Heublein D; Bailey KR; Burnett JC
Am Heart J; 2005 Mar; 149(3):541-7. PubMed ID: 15864245
[TBL] [Abstract][Full Text] [Related]
12. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol.
Jourdain P; Funck F; Fulla Y; Hagege A; Bellorini M; Guillard N; Loiret J; Thebault B; Desnos M
Eur J Heart Fail; 2002 Jun; 4(3):269-76. PubMed ID: 12034151
[TBL] [Abstract][Full Text] [Related]
13. Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure.
Susa T; Kobayashi S; Tanaka T; Murakami W; Akashi S; Kunitsugu I; Okuda S; Doi M; Wada Y; Nao T; Yamada J; Ueyama T; Okamura T; Yano M; Matsuzaki M
Circ J; 2012; 76(1):117-26. PubMed ID: 22008315
[TBL] [Abstract][Full Text] [Related]
14. Dobutamine stress 99mTc-tetrofosmin quantitative gated SPECT predicts improvement of cardiac function after carvedilol treatment in patients with dilated cardiomyopathy.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Tange S; Suzuki T; Kurabayashi M
J Nucl Med; 2004 Nov; 45(11):1878-84. PubMed ID: 15534058
[TBL] [Abstract][Full Text] [Related]
15. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
Gundogdu F; Bozkurt E; Kiziltunc A; Sevimli S; Arslan S; Gurlertop Y; Senocak H; Karakelleoglu S
Echocardiography; 2007 Feb; 24(2):113-7. PubMed ID: 17313541
[TBL] [Abstract][Full Text] [Related]
16. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Richards AM; Doughty R; Nicholls MG; MacMahon S; Sharpe N; Murphy J; Espiner EA; Frampton C; Yandle TG;
J Am Coll Cardiol; 2001 Jun; 37(7):1781-7. PubMed ID: 11401111
[TBL] [Abstract][Full Text] [Related]
17. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
[TBL] [Abstract][Full Text] [Related]
18. The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
Khand AU; Chew PG; Douglas H; Jones J; Jan A; Cleland JG
Cardiology; 2015; 130(3):153-8. PubMed ID: 25660493
[TBL] [Abstract][Full Text] [Related]
19. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment.
Kawai K; Hata K; Takaoka H; Kawai H; Yokoyama M
Am Heart J; 2001 Jun; 141(6):925-32. PubMed ID: 11376305
[TBL] [Abstract][Full Text] [Related]
20. Restrictive filling pattern predicts pulmonary hypertension and is associated with increased BNP levels and impaired exercise capacity in patients with heart failure.
Straburzyńska-Migaj E; Szyszka A; Trojnarska O; Cieśliński A
Kardiol Pol; 2007 Sep; 65(9):1049-55; discussion 1056-7. PubMed ID: 17975752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]